Phytol/Phytanic Acid and Insulin Resistance: Potential Role of Phytanic Acid Proven by Docking Simulation and Modulation of Biochemical Alterations

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Elmazar, Mohamed M ^a   El Abhar, Hanan S ^b   Schaalan, Mona F ^c   Farag, Nahla A ^c  

^a British Universityin Cairo (BUE)   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Egypt   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMINO ACID; ARGININE; CELL NUCLEUS RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHYTANIC ACID; PHYTOL; PIOGLITAZONE; RETINOIC ACID; RETINOID X RECEPTOR ALPHA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ARTICLE; BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE HOMEOSTASIS; HYDROGEN BOND; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; MALE; MOLECULAR DOCKING; MOLECULAR RECOGNITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT;

ALGORITHMS; ANIMALS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; HYDROGEN BONDING; INSULIN RESISTANCE; LIGANDS; MALE; MOLECULAR DOCKING SIMULATION; PHYTANIC ACID; PHYTOL; PPAR GAMMA; PROTEIN BINDING; RATS; RATS, WISTAR; RETINOID X RECEPTOR ALPHA; SOFTWARE;

RATTUS;

EID: 84871762669     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045638     Document Type: Article

References (47)

1. Astrup A, Finer N, (2000) Redefining type-2 diabetes: 'Diabesity' or 'obesity dependent diabetes mellitus'? Obesity Reviews 1: 57-9.
2. Basciano H, Federico L, Adeli K, (2005) Fructose, insulin resistance, and metabolic dyslipidemia. Nutrition and Metabolism 2: 1-5.
3. McCarty MF, (2005) Up-regulation of PPARgamma coactivator-1alpha as a strategy for preventing and reversing insulin resistance and obesity. Medical Hypotheses 64: 399-407.
4. DeFronzo RA, (1999) Pharmacologic therapy for type-2 diabetes mellitus. Ann Intern Med 131: 281-303.
5. Spiegelman BM, (1998) PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-14.
6. McCarty MF, (2001) The chlorophyll metabolite phytanic acid is a natural rexinoid-potential for treatment and prevention of diabetes. Medical Hypotheses 56: 217-19.
7. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, et al. (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386: 407-10.
8. Villarroya F, Iglesias R, Giralt M, (2004) Retinoids and retinoid receptors in the control of energy balance: novel pharmacological strategies in obesity and diabetes. Curr Med Chem 11: 795-805.
9. Canan Koch SS, Dardashti LJ, Cesario RM, Croston GE, Boehm MF, et al. (1999) Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells. J Med Chem 42: 742-50.
10. Hansen RP, (1966) Occurence of phytanic acid in rumen bacteria. Nature 210: 841.
11. Brown PJ, Mei G, Gibberd FB, Burston D, Mayne PD, et al. (1993) Diet and Refsum's disease. The determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsum's disease. J Hum Nutr Diet 6: 295-305.
12. Gloerich J, van Vlies N, Jansen GA, Denis S, Ruiter JP, et al. (2005) A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPAR alpha dependent and- independent pathways. J Lipid Res 46: 716-26.
13. van den Brink DM, van Miert JN, Dacremont G, Rontani JF, Wanders RJ, (2005) Characterization of the final step in the conversion of phytol into phytanic acid. J BiolChem 280: 26838-44.
14. Heim M, Johnson J, Boess F, Bendik I, Weber P, et al. (2002) Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J 16: 718-20.
15. Elmazar MMA, Nau H, (2004) Potentiation of the teratogenic effects induced by coadministration of retinoic acid or phytanic acid/phytol with synthetic retinoid receptor ligands. Arch Toxicol 78: 660-8.
16. Gloerich J, van den Brink DM, Ruiter JPN, van Vlies N, Vaz FM, et al. (2007) Metabolism of phytol to phytanic acid in the mouse, and the role of PPARα in its regulation. J Lipid Res 48: 77-85.
17. Schaalan M, El-Abhar HS, Barakat M, El-Denshary ES, (2009) Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. J Diabetes Complications 23: 199-208.
18. Murcko MA, Stouten PFW (1997) In:Charifson PS (ed) Practical Application of Computer-Aided Drug Design, Marcel Dekker, New York, pp 355.
19. Anderson A, Weng ZJ, (1999) Molecular Graphics & Modeling 17,180.
20. Halperin I, Ma B, Wolfson H, Nussinov R, (2002) Proteins: Structure, Function, and Genetics,. 47: 409.
21. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395: 137-143.
22. Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, et al. (2000) Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5: 545-555.
23. Levy J, Gavin JR 3rd, Fausto A, Gingerich RL, Avioli LV, (1984) Impaired insulin action in rats with non-insulin-dependent diabetes. Diabetes 33: 901-6.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: Insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-19.
25. Bligh EG, Dyer WJ, (1959) A rapid method of total lipid extraction and purification. Can J BiochemPhysiol 37: 911-17.
26. Allen NE, Grace PB, Ginn A, Travis RC, Roddam AW, et al. (2008) Phytanic acid: measurement of plasma concentrations by gas-liquid chromatography-mass spectrometry analysis and associations with diet and other plasma fatty acids. Br J Nutr 99 (3) (): 653-9.
27. Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, et al. (2000) Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49: 1517-24.
28. Jay MA, Ren J, (2007) Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type-2 diabetes mellitus. Curr Diabetes Rev 3: 33-9.
29. Van den Branden C, Vamecq J, Wybo I, Roels F, (1986) Phytol and peroxisome proliferation. Pediatr Res 20: 411-5.
30. Hashimoto T, Shimizu N, Kimura T, Takahashi Y, Ide T, (2006) Polyunsaturated fats attenuate the dietary phytol-induced increase in hepatic fatty acid oxidation in mice. J Nutr 136: 882-6.
31. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, et al. (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24: 710-9.
32. Miyazaki Y, Mahankali A, Matsuda M, (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type-2 diabetic patients. J ClinEndocrinolMetab 87: 2784-91.
33. Tsuchida A, Yamauchi T, Takekawa S, (2005) Peroxisome proliferator-activated receptor (PPAR)-α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue comparison of activation of PPARα, PPARγ, and their combination. Diabetes 54: 3358-70.
34. Yamauchi T, Kamon J, Waki H, (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-6.
35. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM, (1994) Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Nat AcadSci USA 91: 4854-8.
36. Stefan N, Vozarova B, Funahashi T, (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 50: 1884-8.
37. Iwaki M, Matsuda M, Maeda N, (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655-63.
38. Yamauchi T, Kamon J, Minokoshi Y, (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP activated protein kinase. Nat Med 8: 1288-95.
39. Maeda N, Takahashi M, Funahashi T, (2001) PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-99.
40. Vozarova B, Stefan N, Lindsay RS, (2002) High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type-2 diabetes. Diabetes 51: 1889-95.
41. Hofmann C, Lorenz K, Colca JR, (1991) Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129: 1915-25.
42. Srinivasan K, Patole PS, Kaul CL, Ramarao P, (2004) Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol 26: 327-33.
43. Vijay SK, Mishra M, Kumar H, Tripathi K, (2009) Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol 46: 27-33.
44. Iwata M, Haruta T, Usui I, Takata Y, Takano A, et al. (2001) Pioglitazone ameliorates tumor necrosis factor-α-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-γ. Diabetes 50: 1083-92.
45. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, et al. (2004) Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89: 4312-19.
46. Ding S, Shen Z, Chen Y, Sun S, Liu Q, et al. (2005) Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacologica Sinica 26: 575-80.
47. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, et al. (2000) Activation of human peroxisome proliferators-activated receptor (PPAR) types by pioglitazone. Biochem Biophys Res Commun 278: 704-11.